English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Treatment of Guillain‐Barré syndrome with a standard course of high‐dose intravenous immunoglobulin ( IVI g) results in a variable clinical recovery which is associated with changes in serum IgG levels after treatment. The neonatal Fc‐receptor protects IgG from degradation, and a genetic polymorphism in its promoter region that influences the expression of Fc‐receptor, may in part explain the variation in IgG levels and outcome. This polymorphism was determined by polymerase chain reaction in a cohort of 257 patients with Guillain‐Barré syndrome treated with  IVI g. We could not demonstrate a relation between this polymorphism, the pharmacokinetics of  IVI g, or the clinical course and outcome.

Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVI g or the clinical course of GBS